Similar articles for PMID: 11304102

Year	Number of Results
1926	1
1948	1
1992	1
1995	1
1996	3
1998	1
1999	3
2000	10
2001	17
2002	14
2003	17
2004	11
2005	9
2006	2
2007	4
2008	7
2009	6
2010	5
2011	5
2012	1
2013	3
2014	2
2015	2
2016	4
2017	2
2018	1
2019	1
2020	3
2021	1
2022	1
2024	0

1

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Mann JF, et al. Ann Intern Med. 2001 Apr 17;134(8):629-36. doi: 10.7326/0003-4819-134-8-200104170-00007. Ann Intern Med. 2001. PMID: 11304102 Clinical Trial.

2

Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure.

[No authors listed] [No authors listed] Ann Intern Med. 2001 Apr 17;134(8):S-96. doi: 10.7326/0003-4819-134-8-200104170-00002. Ann Intern Med. 2001. PMID: 11324633 Clinical Trial. No abstract available.

3

Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.

Mann JF. Mann JF. Presse Med. 2005 Oct 22;34(18):1303-8. doi: 10.1016/s0755-4982(05)84178-8. Presse Med. 2005. PMID: 16269994 Free article. Review.

4

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.

Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S; HOPE Investigators. Mann JF, et al. Am J Kidney Dis. 2003 Nov;42(5):936-42. doi: 10.1016/j.ajkd.2003.07.015. Am J Kidney Dis. 2003. PMID: 14582037 Clinical Trial.

5

Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.

Mann JF, Gerstein HC, Pogue J, Lonn E, Yusuf S. Mann JF, et al. Am J Cardiovasc Drugs. 2002;2(3):157-62. doi: 10.2165/00129784-200202030-00003. Am J Cardiovasc Drugs. 2002. PMID: 14727978 Review.

6

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.

7

The kidney in cardiovascular disease.

Kasiske BL. Kasiske BL. Ann Intern Med. 2001 Apr 17;134(8):707-9. doi: 10.7326/0003-4819-134-8-200104170-00014. Ann Intern Med. 2001. PMID: 11304109 No abstract available.

8

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. Heerspink HJ, et al. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4. Eur J Prev Cardiol. 2014. PMID: 24191305 Clinical Trial.

9

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J; DIABHYCAR Study Investigators. Marre M, et al. BMJ. 2004 Feb 28;328(7438):495. doi: 10.1136/bmj.37970.629537.0D. Epub 2004 Feb 11. BMJ. 2004. PMID: 14960504 Free PMC article. Clinical Trial.

10

Spotlight on ramipril in the prevention of cardiovascular outcomes.

Warner GT, Perry CM. Warner GT, et al. Am J Cardiovasc Drugs. 2003;3(2):113-6. doi: 10.2165/00129784-200303020-00005. Am J Cardiovasc Drugs. 2003. PMID: 14727938 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

134 results

Results by year